• 1
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. In: DrossmanDA, ed. Rome II: the Functional Gastrointestinal Disorders. McLean, VA, USA: Degnon, 2000: 299350.
  • 2
    Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 175680.
  • 3
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II3742.
  • 4
    Shaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004; 99: 22106.
    Direct Link:
  • 5
    El-Serag HB, Talley NJ. Systemic review: The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 64354.
  • 6
    Chang L. Review article: Epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 319.
  • 7
    Heikkinen M, Pikkarainen P, Takala J, Rasanen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995; 30: 51923.
  • 8
    Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92 (5 Pt 1): 12824.
  • 9
    Heikkinen M, Farkkila M. What is the long-term outcome of the different subgroups of functional dyspepsia? Aliment Pharmacol Ther 2003; 18: 2239.
  • 10
    Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 290514.
  • 11
    Corsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 11529.
    Direct Link:
  • 12
    Cremonini F, Talley NJ. Review article: The overlap between functional dyspepsia and irritable bowel syndrome – a tale of one or two disorders? Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 409.
  • 13
    Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004; 18: 695706.
  • 14
    Locke GR III, Weaver AL, Melton LJ III, Talley NJ. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 3507.
    Direct Link:
  • 15
    Pajala M, Heikkinen M, Hintikka J. Mental distress in patients with functional or organic dyspepsia: a comparative study with a sample of the general population. Aliment Pharmacol Ther 2005; 21: 27781.
  • 16
    Jones MP, Sharp LK, Crowell MD. Psychosocial correlates of symptoms in functional dyspepsia. Clin Gastroenterol Hepatol 2005; 3: 5218.
  • 17
    Nyren O, Lindberg G, Lindstrom E, Marke LA, Seensalu R. Economic costs of functional dyspepsia [see comments]. Pharmacoeconomics 1992; 1: 31224.
  • 18
    Halder SL, Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 23342.
  • 19
    Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000; 95: 6771.
    Direct Link:
  • 20
    Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 5849.
  • 21
    Fischler B, Tack J, De Gucht V, et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124: 90310.
  • 22
    Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 8390.
  • 23
    Stanghellini V, Tosetti C, Paternic A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 103642.
  • 24
    Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 134652.
  • 25
    Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 105565.
  • 26
    Quartero AO, De Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43: 202833.
  • 27
    Perri F, Clemente R, Festa V, et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998; 93: 20828.
    Direct Link:
  • 28
    Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol 2001; 96: 14228.
    Direct Link:
  • 29
    Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 7838.
    Direct Link:
  • 30
    Pallotta N, Pezzotti P, Calabrese E, Baccini F, Corazziari E. Relationship between gastrointestinal and extra-gastrointestinal symptoms and delayed gastric emptying in functional dyspeptic patients. World J Gastroenterol 2005; 11: 437581.
  • 31
    Talley NJ, Locke GR III, Lahr B, et al. Functional dyspepsia, delayed gastric emptying and impaired quality of life. Gut 2005; 55: 933939.
  • 32
    Delgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127: 168594.
  • 33
    Kim DY, Delgado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 2001; 96: 3099105.
    Direct Link:
  • 34
    Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GN. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 408.
    Direct Link:
  • 35
    Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil 2003; 15: 44755.
  • 36
    Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 123955.
  • 37
    Savoye G, Bouin M, Denis P, Ducrotte P. Delayed postprandial fundic relaxation: a new abnormal finding in functional dyspepsia. Scand J Gastroenterol 2005; 40: 3545.
  • 38
    Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 949.
  • 39
    Lin Z, Eaker EY, Sarosiek I, McCallum RW. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol 1999; 94: 23849.
    Direct Link:
  • 40
    Jebbink HJ, Van Berge-Henegouwen GP, Akkermans LM, Smout AJ. Small intestinal motor abnormalities in patients with functional dyspepsia demonstrated by ambulatory manometry. Gut 1996; 38: 694700.
  • 41
    Simren M, Vos R, Janssens J, Tack J. Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. Am J Gastroenterol 2003; 98: 216975.
  • 42
    Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42: 81422.
  • 43
    Rhee PL, Kim YH, Son HJ, et al. Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia. Dig Dis Sci 2000; 45: 16804.
  • 44
    Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 52635.
  • 45
    Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 1995; 7: 10517.
  • 46
    Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 34755.
  • 47
    Samsom M, Verhagen MA, Van Berge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 51520.
  • 48
    Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology 2001; 120: 36976.
  • 49
    Vandenbergh J, Dupont P, Fischler B, et al. Regional brain activation during proximal stomach distention in humans: a positron emission tomography study. Gastroenterology 2005; 128: 56473.
  • 50
    Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98104.
  • 51
    Spiller RC. Inflammation as a basis for functional GI disorders. Best Pract Res Clin Gastroenterol 2004; 18: 64161.
  • 52
    Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 173847.
  • 53
    Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000; 160: 11928.
  • 54
    Hall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol 2003; 1: 3639.
  • 55
    Hausken T, Svebak S, Wilhelmsen I, et al. Low vagal tone and antral dysmotility in patients with functional dyspepsia. Psychosom Med 1993; 55: 1222.
  • 56
    Holtmann G, Goebell H, Jockenhoevel F, Talley NJ. Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut 1998; 42: 5016.
  • 57
    Berstad A. Functional dyspepsia – a conceptual framework. Gut 2000; 47 (Suppl. 4): iv34; discussion iv10.
  • 58
    Geeraerts B, Vandenberghe J, Van Oudenhove L, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology 2005; 129: 143744.
  • 59
    Hsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002; 51: 1520.
  • 60
    Lieberman D, Fennerty MB, Morris CD, Holub J, Eisen G, Sonnenberg A. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology 2004; 127: 106775.
  • 61
    Fransen GA, Janssen MJ, Muris JW, Laheij RJ, Jansen JB. Meta-analysis: The diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther 2004; 20: 104552.
  • 62
    Janssen HA, Muris JW, Knottnerus JA. The clinical course and prognostic determinants of non-ulcer dyspepsia: a literature review. Scand J Gastroenterol 1999; 34: 54650.
  • 63
    Nojkov B, Chey WD, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Gastroenterology 2005; 128 (Suppl. 2): A-61 (abstract).
  • 64
    Feinle-Bisset C, Vozzo R, Horowitz M, Talley NJ. Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol 2004; 99: 17081.
    Direct Link:
  • 65
    Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995; 40: 163641.
  • 66
    Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol 2005; 20: 165260.
  • 67
    Malfertheiner P, Fischbach W, Layer P, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 61525.
  • 68
    Gisbert JP, Cruzado AI, Garcia-Gravalos R, Pajares JM. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. Hepatogastroenterology 2004; 51: 3038.
  • 69
    Veldhuyzen van Zanten SJ, Fedorak RN, Lambert J, Cohen L, Vanjaka A. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98: 19639.
  • 70
    Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003; 52: 406.
  • 71
    Koskenpato J, Farkkila M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol 2001; 96: 286672.
    Direct Link:
  • 72
    Veldhuyzen van Zanten SJ, Talley NJ, Blum AL, Bolling-Sternevald E, Sundin M, Junghard O. Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms? Gut 2002; 50 (Suppl. 4): iv2630; discussion iv31–2.
  • 73
    Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003; 1: CD002096.
  • 74
    Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 3619.
  • 75
    Danesh J, Pounder RE. Eradication of Helicobacter pylori and non-ulcer dyspepsia. Lancet 2000; 355: 7667.
  • 76
    Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319: 10404.
  • 77
    Laheij RJ, Jansen JB, Van De Lisdonk EH, Severens JL, Verbeek AL. Review article: Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10: 84350.
  • 78
    Laheij RJ, Van Rossum LG, Verbeek AL, Jansen JB. Helicobacter pylori infection treatment of nonulcer dyspepsia: an analysis of meta-analyses. J Clin Gastroenterol 2003; 36: 31520.
  • 79
    Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; 1: CD002096.
  • 80
    Chey WD, Moayyedi P. Review article: Uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 18.
  • 81
    Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 718.
  • 82
    Nyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986; 314: 33943.
  • 83
    Weberg R, Aubert E, Dahlberg O, et al. Low-dose antacids or cimetidine for duodenal ulcer? Gastroenterology 1988; 95: 14659.
  • 84
    Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004; 4: CD001960.
  • 85
    Moayyedi P, Soo S, Deeks J, et al. Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003; 17: 121527.
  • 86
    Redstone HA, Barrowman N, Veldhuyzen van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 12919.
  • 87
    Abraham NS, Moayyedi P, Daniels B, Veldhuyzen van Zanten SJ. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19: 63141.
  • 88
    Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 132937.
  • 89
    Meineche-Schmidt V. Classification of dyspepsia and response to treatment with proton-pump inhibitors. Aliment Pharmacol Ther 2004; 20: 11719.
  • 90
    Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005; 54: 45560.
  • 91
    Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 165361.
  • 92
    Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 68996.
  • 93
    Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 95967.
  • 94
    Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005; 21 (Suppl. 2): 3741.
  • 95
    Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005; 21 (Suppl. 2): 426.
  • 96
    Van Der Voort I, Schmidtmann M, Fach K, et al. Tegaserod improves gastric emptying and alters myoelectric activity in dyspeptic patients. Gastroenterology 2004; 126 (Suppl. 2): A-643.
  • 97
    Tack J, Vos R, Bisschops G, Tougas G, Janssens J, Phillipps T. Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology 2005; 128 (Suppl. 2): A-94 (abstract).
  • 98
    Tougas G, Chen Y, Luo D, Salter J, D'Elia T, Earnest D. Tegaserod improves gastric emptying in patients with gastroeparesis and dyspeptic symptoms. Gastroenterology 2003; 124 (Suppl. 1): A-54 (abstract).
  • 99
    Mearin F, Rodrigo L, Perez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004; 2: 3018.
  • 100
    Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 83240.
  • 101
    Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005; 40: 103642.
  • 102
    Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy vs. education and desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 1931.
  • 103
    Dalton C, Diamant NE, Morris CB, et al. Are side effects of tricyclic antidepressants (TCAs) really side effects? Gastroenterology 2004; 126 (Suppl. 2): A-250.
  • 104
    Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 1605.
    Direct Link:
  • 105
    Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002; 51 (Suppl. 1): i915.
  • 106
    Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275 (3 Pt 1): G4606.
  • 107
    Tack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 6038.
  • 108
    Ladabaum U, Glidden D. Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 2002; 14: 395402.
  • 109
    Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996; 91: 27783.
  • 110
    Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123: 177885.
  • 111
    Haug TT, Wilhelmsen I, Svebak S, Berstad A, Ursin H. Psychotherapy in functional dyspepsia. J Psychosom Res 1994; 38: 73544.
  • 112
    Mine K, Kanazawa F, Hosoi M, Kinukawa N, Kubo C. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions. Dig Dis Sci 1998; 43: 12417.
  • 113
    Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119: 6619.
  • 114
    Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004; 99: 181722.
    Direct Link:
  • 115
    Thompson Coon J, Ernst E. Systematic review: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002; 16: 168999.
  • 116
    Melzer J, Rosch W, Reichling J, Brignoli R, Saller R. Meta-analysis: Phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 127987.
  • 117
    Bortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002; 16: 107582.
  • 118
    Rodriguez-Stanley S, Collings KL, Robinson M, Owen W, Miner PB Jr. The effects of capsaicin on reflux, gastric emptying and dyspepsia. Aliment Pharmacol Ther 2000; 14: 12934.
  • 119
    Holtmann G, Adam B, Haag S, Collet W, Grunewald E, Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003; 18: 1099105.
  • 120
    Read NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine vs. placebo in the treatment of functional dyspepsia. Gut 1997; 41: 6648.
  • 121
    Delgado-Aros S, Chial HJ, Cremonini F, et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003; 18: 50714.
  • 122
    Stanghellini V, De Ponti F, De Giorgio R, Barbara G, Tosetti C, Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs 2003; 63: 86992.
  • 123
    Holzer P. Acid-sensitive ion channels in gastrointestinal function. Curr Opin Pharmacol 2003; 3: 61825.
  • 124
    Honore P, Mikusa J, Bianchi B, et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 2002; 96: 99105.
  • 125
    Ide Y, Maehara Y, Tsukahara S, Kitahata LM, Collins JG. The effects of an intrathecal NMDA antagonist (AP5) on the behavioral changes induced by colorectal inflammation with turpentine in rats. Life Sci 1997; 60: 135963.
  • 126
    Kuiken SD, Lei A, Tytgat GN, Holman R, Boeckxstaens GE. Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 195562.
  • 127
    Kawabata A. Gastrointestinal functions of proteinase-activated receptors. Life Sci 2003; 74: 24754.
  • 128
    Kawabata A, Kinoshita M, Nishikawa H, et al. The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 2001; 107: 144350.
  • 129
    Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465: 12135.
  • 130
    Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 17793.
  • 131
    Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52: 155561.
  • 132
    Mearadji B, Straathof JW, Biemond I, Lamers CB, Masclee AA. Effects of somatostatin on proximal gastric motor function and visceral perception. Aliment Pharmacol Ther 1998; 12: 11639.
  • 133
    Mertz H, Walsh JH, Sytnik B, Mayer EA. The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995; 7: 17585.
  • 134
    Feinle C, Rades T, Otto B, Fried M. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology 2001; 120: 11007.
  • 135
    Holzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001; 1: 58390.
  • 136
    Monnikes H, Tebbe JJ, Hildebrandt M, et al. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis 2001; 19: 20111.
  • 137
    Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986; 77: 9926.
  • 138
    Moran TH, McHugh PR. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 1982; 242: R4917.
  • 139
    Chua AS, Keeling PW, Dinan TG. Role of cholecystokinin and central serotonergic receptors in functional dyspepsia. World J Gastroenterol 2006; 12: 132935.
  • 140
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 30908.
  • 141
    Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290300.
  • 142
    Hill R. NK1 (substance P) receptor antagonists – why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 2446.
  • 143
    Sanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004; 141: 130312.
  • 144
    Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 30411.
  • 145
    Tache Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci 1999; 44 (Suppl. 8): 79S86S.
  • 146
    Chen CY, Inui A, Asakawa A, et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 2005; 129: 825.
  • 147
    Luckey A, Wang L, Jamieson PM, et al. Corticotropin-releasing factor receptor 1-deficient mice do not develop postoperative gastric ileus. Gastroenterology 2003; 125: 6549.
  • 148
    Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 52537.
  • 149
    De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53: 152035.
  • 150
    Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 146679.